| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab2edb7c1788ec671c8b8aad5805b178 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate |
2016-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03fb06d46da40a3ea4f9ea7188bd5804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e7c731fcd91ad9c649471f6df3b10af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d50b6b0e1cd987280c1fc3fe9536e8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7a6106944fe3fb3d9f7bdf6ba547547
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1351be3b088c1fcf78dffb88869d6ac7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1bccc98cb4003aa716333c687af1a77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab852c34234d6454b3bffd828ed8d91b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f865ea44c7463709f7a585e52b91117f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6962532d0a7a93850087a6af814f05f8 |
| publicationDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2623064-C1 |
| titleOfInvention |
Method for fetoplacental insufficiency prevention for pregnant women with chronic kidney disease |
| abstract |
FIELD: medicine. n SUBSTANCE: invention is intended for prevention of fetoplacental insufficiency (FPI) for pregnant women with chronic kidney disease (CKD). An antiaggregant is prescribed at a preventive dose. In addition, pregnant women with pathology interstitial at CKD of stages III-V, glomerulopathies at CKD receive heparin therapy at a preventive dose. For pregnant women with stage II CKD, plasma hemostasis is examined by thrombodynamics and if at least two spontaneous clots are detected during 30 minutes of observation, heparin therapy is carried out at a preventive dose. Further, the state of the plasma hemostasis is monitored by thrombodynamics at least once every 20 days. If at least two spontaneous clots are detected within 30 minutes of observation, the preventive dose of heparin is adjusted upwards. n EFFECT: method allows to provide prevention of fetoplacental insufficiency. n 3 ex |
| priorityDate |
2016-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |